You are now leaving the Novartis Venture Fund website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.
Continue
|
Cancel
LigoCyte Pharmaceuticals is focused at novel vaccines based on its proprietary virus-like particle technology platform. The lead project is a Norovirus and Influenza vaccine.